Adapting international clinical trials during COVID-19 and beyond.

COVID-19 clinical trial management clinical trials network malaria trials remote monitoring virtual training

Journal

Clinical trials (London, England)
ISSN: 1740-7753
Titre abrégé: Clin Trials
Pays: England
ID NLM: 101197451

Informations de publication

Date de publication:
Jun 2023
Historique:
medline: 12 6 2023
pubmed: 12 2 2023
entrez: 11 2 2023
Statut: ppublish

Résumé

The COVID-19 pandemic and resulting restrictions, particularly travel restrictions, have had significant impact on the conduct of global clinical trials. Our clinical trials programme, which relied on in-person visits for training, monitoring and capacity building across nine low- and middle-income countries, had to adapt to those unprecedented operational challenges. We report the adaptation of our working model with a focus on the operational areas of training, monitoring and cross-site collaboration. Adaptations include changing training strategies from in-person site visits with three or four team members to a multi-pronged virtual approach, with generic online training for good clinical practice, the development of a library of study-specific training videos, and interactive virtual training sessions, including practical laboratory-focused training sessions. We also report changes from in-person monitoring to remote monitoring as well as the development of a more localized network of clinical trial monitors to support hybrid models with in-person and remote monitoring depending on identified risks at each site. We established a virtual network across different trial and study sites with the objective to further build capacity for good clinical practice-compliant antimalarial trials and foster cross-country and cross-study site collaboration. The forced adaptation of these new strategies has come with advantages that we did not envisage initially. This includes improved, more frequent engagement through the established network with opportunities for increased south-to-south support and a substantially reduced carbon footprint and budget savings. Our new approach is challenging for study sites with limited prior experience but this can be overcome with hybrid models. Capacity building for laboratory-based work remains difficult using a virtual environment. The changes to our working model are likely to last, even after the end of the pandemic, providing a more sustainable and equitable approach to our research.

Sections du résumé

BACKGROUND UNASSIGNED
The COVID-19 pandemic and resulting restrictions, particularly travel restrictions, have had significant impact on the conduct of global clinical trials. Our clinical trials programme, which relied on in-person visits for training, monitoring and capacity building across nine low- and middle-income countries, had to adapt to those unprecedented operational challenges. We report the adaptation of our working model with a focus on the operational areas of training, monitoring and cross-site collaboration.
THE NEW WORKING MODEL UNASSIGNED
Adaptations include changing training strategies from in-person site visits with three or four team members to a multi-pronged virtual approach, with generic online training for good clinical practice, the development of a library of study-specific training videos, and interactive virtual training sessions, including practical laboratory-focused training sessions. We also report changes from in-person monitoring to remote monitoring as well as the development of a more localized network of clinical trial monitors to support hybrid models with in-person and remote monitoring depending on identified risks at each site. We established a virtual network across different trial and study sites with the objective to further build capacity for good clinical practice-compliant antimalarial trials and foster cross-country and cross-study site collaboration.
CONCLUSION UNASSIGNED
The forced adaptation of these new strategies has come with advantages that we did not envisage initially. This includes improved, more frequent engagement through the established network with opportunities for increased south-to-south support and a substantially reduced carbon footprint and budget savings. Our new approach is challenging for study sites with limited prior experience but this can be overcome with hybrid models. Capacity building for laboratory-based work remains difficult using a virtual environment. The changes to our working model are likely to last, even after the end of the pandemic, providing a more sustainable and equitable approach to our research.

Identifiants

pubmed: 36772825
doi: 10.1177/17407745231154215
pmc: PMC9922661
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

237-241

Auteurs

Kamala Thriemer (K)

Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.

Tamiru Shibiru Degaga (TS)

College of Medicine & Health Sciences, Arba Minch University, Arba Minch, Ethiopia.

Mohammad Shafiul Alam (MS)

International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B), Dhaka, Bangladesh.

Bipin Adhikari (B)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.

Rupam Tripura (R)

Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.

Mohammad Sharif Hossain (MS)

International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B), Dhaka, Bangladesh.

Michael Christian (M)

Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia.

Najia K Ghanchi (NK)

Department of Pathology and Microbiology, Aga Khan University, Karachi, Pakistan.

Hellen Mnjala (H)

Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.

Sophie Weston (S)

Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.

Benedikt Ley (B)

Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.

Angela Rumaseb (A)

Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.

Dagimawie Tadesse (D)

College of Medicine & Health Sciences, Arba Minch University, Arba Minch, Ethiopia.

Tedla Teferi (T)

Arba Minch General Hospital, Arba Minch, Ethiopia.

Daniel Yilma (D)

Jimma University, Jimma, Ethiopia.

Grant Lee (G)

Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.

Holger Unger (H)

Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.

Inge Sutanto (I)

Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.

Ayodhia Pitaloka Pasaribu (AP)

Department of Child Health, Universitas Sumatera Utara, Medan, Indonesia.

Prakash Ghimire (P)

Central Department of Microbiology, Tribhuvan University, Kirtipur, Nepal.

Mohammad Asim Beg (MA)

Department of Pathology and Microbiology, Aga Khan University, Karachi, Pakistan.

Ric N Price (RN)

Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.
Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH